Multiplex RT Real-Time PCR Based on Target Failure to Detect and Identify Different Variants of SARS-CoV-2: A Feasible Method That Can Be Applied in Clinical Laboratories.
Delta variant
Omicron variant
SARS-CoV-2
multiplex reverse transcriptase real-time PCR
target-failure real-time PCR
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
07 Apr 2023
07 Apr 2023
Historique:
received:
20
02
2023
revised:
17
03
2023
accepted:
30
03
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
Shortly after its emergence, Omicron and its sub-variants have quickly replaced the Delta variant during the current COVID-19 outbreaks in Vietnam and around the world. To enable the rapid and timely detection of existing and future variants for epidemiological surveillance and diagnostic applications, a robust, economical real-time PCR method that can specifically and sensitively detect and identify multiple different circulating variants is needed. The principle of target- failure (TF) real-time PCR is simple. If a target contains a deletion mutation, then there is a mismatch with the primer or probe, and the real-time PCR will fail to amplify the target. In this study, we designed and evaluated a novel multiplex RT real-time PCR (MPL RT-rPCR) based on the principle of target failure to detect and identify different variants of SARS-CoV-2 directly from the nasopharyngeal swabs collected from COVID-19 suspected cases. The primers and probes were designed based on the specific deletion mutations of current circulating variants. To evaluate the results from the MPL RT-rPCR, this study also designed nine pairs of primers for amplifying and sequencing of nine fragments from the S gene containing mutations of known variants. We demonstrated that (i) our MPL RT-rPCR was able to accurately detect multiple variants that existed in a single sample; (ii) the limit of detection of the MPL RT-rPCR in the detection of the variants ranged from 1 to 10 copies for Omicron BA.2 and BA.5, and from 10 to 100 copies for Delta, Omicron BA.1, recombination of BA.1 and BA.2, and BA.4; (iii) between January and September 2022, Omicron BA.1 emerged and co-existed with the Delta variant during the early period, both of which were rapidly replaced by Omicron BA.2, and this was followed by Omicron BA.5 as the dominant variant toward the later period. Our results showed that SARS-CoV-2 variants rapidly evolved within a short period of time, proving the importance of a robust, economical, and easy-to-access method not just for epidemiological surveillance but also for diagnoses around the world where SARS-CoV-2 variants remain the WHO's highest health concern. Our highly sensitive and specific MPL RT-rPCR is considered suitable for further implementation in many laboratories, especially in developing countries.
Identifiants
pubmed: 37189465
pii: diagnostics13081364
doi: 10.3390/diagnostics13081364
pmc: PMC10137618
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Int J Environ Res Public Health. 2022 Jan 24;19(3):
pubmed: 35162303
Pathogens. 2022 Nov 18;11(11):
pubmed: 36422629
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
Nature. 2022 Feb;602(7896):300-306
pubmed: 34823256
J Med Virol. 2022 May;94(5):1808-1810
pubmed: 35043399
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):7173-7191
pubmed: 32633414
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Brief Bioinform. 2021 Mar 22;22(2):616-630
pubmed: 33279989